Mid-cap Health Care company Intra-Cellular Therapies has moved -0.7% so far today on a volume of 329,209, compared to its average of 646,514. In contrast, the S&P 500 index moved 0.0%.
Intra-Cellular Therapies trades -30.74% away from its average analyst target price of $77.83 per share. The 12 analysts following the stock have set target prices ranging from $59.0 to $100.0, and on average have given Intra-Cellular Therapies a rating of buy.
Anyone interested in buying ITCI should be aware of the facts below:
-
Intra-Cellular Therapies has moved 13.0% over the last year, and the S&P 500 logged a change of 23.0%
-
Based on its trailing earnings per share of -1.96, Intra-Cellular Therapies has a trailing 12 month Price to Earnings (P/E) ratio of -27.5 while the S&P 500 average is None
-
ITCI has a forward P/E ratio of -84.2 based on its forward 12 month price to earnings (EPS) of $-0.64 per share
-
The company has a price to earnings growth (PEG) ratio of -0.27 — a number near or below 1 signifying that Intra-Cellular Therapies is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 8.53 compared to its sector average of None
-
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
-
Based in New York, the company has 561 full time employees and a market cap of $5.18 Billion.
